Novel myeloid immune cell mechanisms in tumor progression and immune evasion



Myeloid immune cells are extremely plastic by nature and in a cancer patient they are represented by granulocytes, monocytes, macrophages, dendritic cells and myeloid derived suppressor cells (MDSC). In a cancer context they are major contributors to both systemic immune activation and immunosuppression, the latter resulting in tumor progression and metastases. Tumors skew the immune system towards this immunosuppressive state. The knowledge concerning the mechanisms by which myeloid immune cells affect this tumor progression, and also how myeloid immune cells affect adaptive immune cells in cancer, is fundamentally important, and may explain why only some patients respond to novel immune-oncology therapies. Myeloid immune cells can affect the adaptive immune cells in different ways, some examples being antigen presentation, chemoattraction or exclusion, or regulation. In this project we investigate novel mechanisms regarding how myeloid cells affect tumor progression and immune evasion in cancer.

Our main purpose is to investigate lymph node resident antigen presenting macrophages in lymph nodes, and similar cells in tumors, from breast cancer patients and their relation to NK, T-cell tolerance and tertiary lymphoid structures. How primary tumors may affect lymph node architecture, and to explore mechanisms on how neutrophils regulates monocyte exclusion from tumors.
Gällande start-/slutdatum2021/05/012025/05/01

Ämnesklassifikation (UKÄ)

  • Immunologi inom det medicinska området
  • Cancer och onkologi